Monogram Biosciences (NASDAQ:MGRM), formerly ViroLogic, Inc., develops and commercializes innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. The Company’s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. Monogram’s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics.
People
Tien Bui (Medical-Marketing Consultant)
Alfred Merriweather (CFO)
Christos Petropoulos (VP Scientific Officer)
Jeanette Whitcomb (VP Operations)
Patricia Wray (VP HR)
View more details about all 17 people at Monogram Biosciences
News
Personalized medicine takes a (tiny) step forward
August 8, 2007 8:28 pm
(UPDATED: See below.) For at least a decade, biotech futurists have been predicting that the genomics revolution will lead to… Continue reading ⟩
Insurance companies balking at personalized medications
January 3, 2007 4:02 pm
So-called personalized medicine — tailoring treatments to an individual’s genetic traits — is showing great promise, but insurance companies are… Continue reading ⟩